Literature DB >> 14726483

Nuclear antisense effects in cyclophilin A pre-mRNA splicing by oligonucleotides: a comparison of tricyclo-DNA with LNA.

Damian Ittig1, Songkai Liu, Dorte Renneberg, Daniel Schümperli, Christian J Leumann.   

Abstract

The nuclear antisense properties of a series of tricyclo (tc)-DNA oligonucleotide 9-15mers, targeted against the 3' and 5' splice sites of exon 4 of cyclophilin A (CyPA) pre-mRNA, were evaluated in HeLa cells and compared with those of corresponding LNA-oligonucleotides. While the 9mers showed no significant antisense effect, the 11-15mers induced exon 4 skipping and exon 3+4 double skipping to about an equal extent upon lipofectamine mediated transfection in a sequence- and dose-dependent manner, as revealed by a RT-PCR assay. The antisense efficacy of the tc-oligonucleotides was found to be superior to that of the LNA-oligonucleotides in all cases by a factor of at least 4-5. A tc-oligonucleotide 15mer completely abolished CyPA mRNA production at 0.2 microM concentration. The antisense effect was confirmed by western blot analysis which revealed a reduction in CyPA protein to 13% of its normal level. Fluorescence microscopic investigations with a fluorescein labeled tc-15mer revealed a strong propensity for homogeneous nuclear localization of this backbone type after lipofectamine mediated transfection, while the corresponding lna 15mer showed a less clear cellular distribution pattern. Transfection without lipid carrier showed no significant internalization of both tc- and LNA- oligonucleotides. The obtained results confirm the power of tc-DNA for nuclear antisense applications. Moreover, CyPA may become an interesting therapeutic target due to its important role in the early steps of the viral replication of HIV-1.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14726483      PMCID: PMC373297          DOI: 10.1093/nar/gkh187

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  40 in total

1.  Potent and nontoxic antisense oligonucleotides containing locked nucleic acids.

Authors:  C Wahlestedt; P Salmi; L Good; J Kela; T Johnsson; T Hökfelt; C Broberger; F Porreca; J Lai; K Ren; M Ossipov; A Koshkin; N Jakobsen; J Skouv; H Oerum; M H Jacobsen; J Wengel
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

2.  Modification of alternative splicing of Bcl-x pre-mRNA in prostate and breast cancer cells. analysis of apoptosis and cell death.

Authors:  D R Mercatante; C D Bortner; J A Cidlowski; R Kole
Journal:  J Biol Chem       Date:  2001-02-07       Impact factor: 5.157

3.  Correction of aberrant splicing of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by antisense oligonucleotides.

Authors:  K J Friedman; J Kole; J A Cohn; M R Knowles; L M Silverman; R Kole
Journal:  J Biol Chem       Date:  1999-12-17       Impact factor: 5.157

4.  Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides.

Authors:  J K Taylor; Q Q Zhang; J R Wyatt; N M Dean
Journal:  Nat Biotechnol       Date:  1999-11       Impact factor: 54.908

5.  Deletion of individual exons and induction of soluble murine interleukin-5 receptor-alpha chain expression through antisense oligonucleotide-mediated redirection of pre-mRNA splicing.

Authors:  J G Karras; R A McKay; N M Dean; B P Monia
Journal:  Mol Pharmacol       Date:  2000-08       Impact factor: 4.436

6.  Antisense morpholino oligonucleotide analog induces missplicing of C-myc mRNA.

Authors:  R V Giles; D G Spiller; R E Clark; D M Tidd
Journal:  Antisense Nucleic Acid Drug Dev       Date:  1999-04

7.  Correction of alternative splicing of tau in frontotemporal dementia and parkinsonism linked to chromosome 17.

Authors:  B Kalbfuss; S A Mabon; T Misteli
Journal:  J Biol Chem       Date:  2001-09-17       Impact factor: 5.157

8.  Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs.

Authors:  P Sazani; S H Kang; M A Maier; C Wei; J Dillman; J Summerton; M Manoharan; R Kole
Journal:  Nucleic Acids Res       Date:  2001-10-01       Impact factor: 16.971

9.  Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients.

Authors:  G Lacerra; H Sierakowska; C Carestia; S Fucharoen; J Summerton; D Weller; R Kole
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

10.  Modulation of survival motor neuron pre-mRNA splicing by inhibition of alternative 3' splice site pairing.

Authors:  S R Lim; K J Hertel
Journal:  J Biol Chem       Date:  2001-10-02       Impact factor: 5.157

View more
  12 in total

1.  Improving gene silencing of siRNAs via tricyclo-DNA modification.

Authors:  Damian Ittig; Samuel Luisier; Jan Weiler; Daniel Schümperli; Christian J Leumann
Journal:  Artif DNA PNA XNA       Date:  2010-07

Review 2.  The chemical evolution of oligonucleotide therapies of clinical utility.

Authors:  Anastasia Khvorova; Jonathan K Watts
Journal:  Nat Biotechnol       Date:  2017-02-27       Impact factor: 54.908

3.  TricycloDNA-modified oligo-2'-deoxyribonucleotides reduce scavenger receptor B1 mRNA in hepatic and extra-hepatic tissues--a comparative study of oligonucleotide length, design and chemistry.

Authors:  Sue Murray; Damian Ittig; Erich Koller; Andres Berdeja; Alfred Chappell; Thazha P Prakash; Michaela Norrbom; Eric E Swayze; Christian J Leumann; Punit P Seth
Journal:  Nucleic Acids Res       Date:  2012-03-30       Impact factor: 16.971

4.  Position-dependent effects on stability in tricyclo-DNA modified oligonucleotide duplexes.

Authors:  Damian Ittig; Anna-Barbara Gerber; Christian J Leumann
Journal:  Nucleic Acids Res       Date:  2010-08-17       Impact factor: 16.971

Review 5.  Therapeutic Potential of Tricyclo-DNA antisense oligonucleotides.

Authors:  Aurelie Goyenvalle; Christian Leumann; Luis Garcia
Journal:  J Neuromuscul Dis       Date:  2016-05-27

6.  Short (16-mer) locked nucleic acid splice-switching oligonucleotides restore dystrophin production in Duchenne Muscular Dystrophy myotubes.

Authors:  Vanessa Borges Pires; Ricardo Simões; Kamel Mamchaoui; Célia Carvalho; Maria Carmo-Fonseca
Journal:  PLoS One       Date:  2017-07-24       Impact factor: 3.240

Review 7.  The Use of Tricyclo-DNA Oligomers for the Treatment of Genetic Disorders.

Authors:  Philippine Aupy; Lucía Echevarría; Karima Relizani; Aurélie Goyenvalle
Journal:  Biomedicines       Date:  2017-12-22

8.  Efficacy and Safety Profile of Tricyclo-DNA Antisense Oligonucleotides in Duchenne Muscular Dystrophy Mouse Model.

Authors:  Karima Relizani; Graziella Griffith; Lucía Echevarría; Faouzi Zarrouki; Patricia Facchinetti; Cyrille Vaillend; Christian Leumann; Luis Garcia; Aurélie Goyenvalle
Journal:  Mol Ther Nucleic Acids       Date:  2017-06-22       Impact factor: 8.886

9.  Design and evaluation of locked nucleic acid-based splice-switching oligonucleotides in vitro.

Authors:  Takenori Shimo; Keisuke Tachibana; Kiwamu Saito; Tokuyuki Yoshida; Erisa Tomita; Reiko Waki; Tsuyoshi Yamamoto; Takefumi Doi; Takao Inoue; Junji Kawakami; Satoshi Obika
Journal:  Nucleic Acids Res       Date:  2014-06-16       Impact factor: 16.971

10.  From Cryptic Toward Canonical Pre-mRNA Splicing in Pompe Disease: a Pipeline for the Development of Antisense Oligonucleotides.

Authors:  Atze J Bergsma; Stijn Lm In 't Groen; Frans W Verheijen; Ans T van der Ploeg; W W M Pim Pijnappel
Journal:  Mol Ther Nucleic Acids       Date:  2016-09-13       Impact factor: 10.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.